The Drug Your Health Insurance Renewal Is Afraid to Name

Your next health insurance renewal probably already contains a GLP-1 problem. Most employers just have not identified it yet. Behind the 9%, 14%, and 20% renewal increases showing up across the country is a pharmaceutical cost wave that is rapidly reshaping employer-sponsored health insurance — and many brokers are still presenting it as "general medical trend."

Ozempic. Wegovy. Mounjaro. Zepbound. A drug class that barely mattered five years ago is now becoming one of the single largest cost drivers in American health plans. National GLP-1 spending increased from approximately $13.7 billion in 2018 to more than $71 billion by 2023. That is not simply growth within a therapeutic category — it is the creation of an entirely new cost category impacting every major employer-sponsored health plan in America.

Why This Is Different From Previous Cost Trends

Employer health plans have dealt with expensive therapies before — specialty drugs, biologics, gene therapies, cancer treatments. GLP-1 medications are different because the potential patient population is dramatically larger than anything employers have previously faced. A specialty drug used by a few hundred members creates one type of actuarial challenge. A medication that may be desired by 20%, 30%, or even 40% of the population creates a completely different challenge.

The Hidden Question Every Employer Should Ask

The most important question is not: "How much are GLP-1 drugs costing us?" The more important question is: "Why are so many employees becoming clinically eligible for them?" That question shifts the discussion from pharmacy management to population health management. It changes the conversation from treatment to prevention. And it forces employers to examine whether they have any meaningful strategy for improving the metabolic health of their workforce.